<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00860821</url>
  </required_header>
  <id_info>
    <org_study_id>D1511M00004</org_study_id>
    <nct_id>NCT00860821</nct_id>
  </id_info>
  <brief_title>A Methodology Study in Healthy Subjects to Evaluate the Effect of AZD8309 After Nasal Administration of Lipopolysaccharide (LPS)</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Two-way Crossover, Single-centre Methodologhy Study in Healthy Subjects to Evaluate the Effect of Oral Dosing With AZD8309 on Cells and Inflammatory Biomarkers in Nasal Lavage and Blood After Nasal Challenge With Lipopolysaccharide (LPS).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this methodology study is to evaluate the effect of AZD8309 on cells and
      inflammatory biomarkers in nasal lavage and blood after nasal challenge with
      lipopolysaccharide (LPS)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neutrophil numbers in nasal lavage</measure>
    <time_frame>3 times each in the end of two treatment periods</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cells and inflammatory biomarkers in nasal lavage</measure>
    <time_frame>3 times in the end of the two treatment periods</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cells and inflammatory biomarkers in blood</measure>
    <time_frame>2 times in the beginning and 5 times in the end of the two treatment periods</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD8309</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD8309</intervention_name>
    <description>oral solution 30 mg/g, dose: 300mg bid for 3 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD8309</intervention_name>
    <description>oral solution 30 mg/g, dose: 300mg bid for 3 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men or healthy, permanently sterilized, women aged 18 to 50 years inclusive,
             non-smokers or ex-smokers, Body Mass Index 18 to 30 kg/m2 and minimum body weight of
             50 kg

          -  Blood neutrophil count above 2.2x10^9/L

        Exclusion Criteria:

          -  Clinical relevant disease and/or abnormality
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Olaf Cardell</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Otorhinolaryngology, Malmö University Hospital, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leif Eriksson</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D Lund, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2009</study_first_submitted>
  <study_first_submitted_qc>March 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2009</study_first_posted>
  <last_update_submitted>October 27, 2009</last_update_submitted>
  <last_update_submitted_qc>October 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2009</last_update_posted>
  <responsible_party>
    <name_title>Leif Eriksson, MD PhD, Medical Science Director, RITA CPT2</name_title>
    <organization>AstraZeneca R&amp;D Lund</organization>
  </responsible_party>
  <keyword>Healthy subjects</keyword>
  <keyword>LPS</keyword>
  <keyword>Effect</keyword>
  <keyword>Intranasally</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

